Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884083 | 0.82 | AKR1B1 (0.41) | MAOAMAOBMEN1KMT2ALMNA | |
| SCHEMBL28475245 | 0.81 | PAM (0.44) | MAOBHDAC1HDAC2HAO1PAM | |
| SCHEMBL11358699 | 0.80 | RECQL (0.46) | HDAC1HDAC2HAO1PAMMEN1 | |
| SCHEMBL2903284 | 0.80 | MEN1 (0.46) | MAOAMAOBHDAC1HDAC2HAO1 | |
| SCHEMBL2906366 | 0.78 | ALDH1A1 (0.53) | PAMMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2903566 | 0.77 | MEN1 (0.43) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL27834761 | 0.77 | MAPT (0.43) | HDAC1HDAC2HAO1LMNAALDH1A1 | |
| SCHEMBL2906150 | 0.76 | MIF (0.43) | HAO1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6622376 | 0.74 | MEN1 (0.50) | MEN1KMT2ALMNAHDAC3RECQL | |
| SCHEMBL10936100 | 0.73 | MAOB (0.40) | MAOBHDAC1HDAC2PAMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973780-B1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO -3-(METHYLHYDRAZONO) METHYL-CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GMBH (AT) | 2003-07-02 | — | — | EP | claimed |
| US-6531465-B1 | 7-acylamino-3-(imino)methyl cephalosporins; 7-[[(5-Amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluormethoxyimino)acetyl]amino]-3-[[(piperazinoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid; imination of 3-methyl derivative; acylation at the 7-amino; 1-[hydrazino(methylimino)methyl]piperazine intermediate | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2003-03-11 | — | — | US | claimed |
| US-5055463-A | Bactericides | MERCK & CO., INC. (US) | 1991-10-08 | — | — | US | claimed |
| US-4937253-A | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| EP-0365149-A2 | Leukotriene antagonist prodrugs | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-25 | — | — | EP | claimed |
| EP-0148883-B1 | ALLOPURINOL PRODRUGS | A/S GEA Farmaceutisk Fabrik (DK) | 1990-02-14 | — | — | EP | claimed |
| US-4694006-A | Acyl- or acyloxymethyl-allopurinol prodrugs | A/S GEA (DK) | 1987-09-15 | — | — | US | claimed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | claimed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | claimed |
| US-4155912-A | 2-Methylpenem-3-carboxylic acid antibiotics | BRISTOL-MYERS COMPANY (US) | 1979-05-22 | — | — | US | claimed |
| CN-112055711-B | Cyclohexylic acid triazolazine as LPA antagonist | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228444-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | RECURSION PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12012374-B2 | Agonists of ROR GAMMAt | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-18 | — | — | US | disclosed |
| US-4041162-A | ANTIBIOTICS, BACTERICIDES | SMITHKLINE CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
| US-4034092-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
| US-4025626-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
| US-4020057-A | 7β-Acyloxy cephalosporins | SMITHKLINE CORPORATION (US) | 1977-04-26 | — | — | US | disclosed |
| US-3965099-A | Cephalosporin esters with antibacterial activity | SMITHKLINE CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228444-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | CYP11B2, CYP11B1, MAPT | AOC2 673/4885MAOA 149/4885MAOB 102/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | AOC2 4045/4885MAOA 3813/4885MAOB 3630/4885 |
| US-12012374-B2 | Agonists of ROR GAMMAt | RORB, RORA, RORC | AOC2 4684/4885MAOA 3378/4885MAOB 3075/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | AOC2 1590/4885MAOA 711/4885MAOB 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.